Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH

Description

This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.

Conditions

Developmental Dysplasia of the Hip

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.

Use of Intraoperative Contrast-enhanced Ultrasound to Evaluate Femoral Head Perfusion in Infants With Developmental Dysplasia of the Hip at the Time of Surgical Reduction

Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH

Condition
Developmental Dysplasia of the Hip
Intervention / Treatment

-

Contacts and Locations

Philadelphia

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19014

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Males or females between 4 months and up to and including 24 months of age at the time of surgery.
  • * Diagnosed with DDH.
  • * Failed conservative treatment and are undergoing closed or open reduction and spica casting.
  • * Informed consent
  • * \> 24 months of age at the time of surgery.
  • * Subjects with DDH who are successfully treated with conservative measures and do not require surgical reduction.
  • * Previous open hip reduction of the affected side
  • * Children with known complex congenital heart disease or unstable cardiopulmonary conditions (as noted in the package labeling for Lumason) including acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure or serious ventricular arrhythmias will be excluded.
  • * History of allergic reaction to Lumason, sulfur hexafluoride, sulfur hexafluoride lipid microsphere components, or other ingredients in Lumason (polyethylene glycol, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Ns), palmitic acid).Parental/guardian permission (informed consent) and if appropriate, child assent.

Ages Eligible for Study

4 Months to 24 Months

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Hospital of Philadelphia,

Wudbhav N Sankar, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Philadelphia

Susan Back, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Philadelphia

Study Record Dates

2028-04